You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
KIOVIG administered intravenously is indicated for:,1. Replacement therapy indications, Primary immunodeficiency disorders (PID);, Symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.,2. Immunomodulation indications, Idiopathic thrombocytopenia purpura (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, Guillain Barré Syndrome;, Kawasaki Disease;, Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in adults., Multifocal Motor Neuropathy (MMN).,KIOVIG administered subcutaneously is indicated for:,1. Replacement therapy indications, Primary immunodeficiency disorders (PID).
KIOVIG administered intravenously is indicated for:,1. Replacement therapy indications, Primary immunodeficiency disorders (PID);, Symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.,2. Immunomodulation indications, Idiopathic thrombocytopenia purpura (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, Guillain Barré Syndrome;, Kawasaki Disease;, Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in adults., Multifocal Motor Neuropathy (MMN).,KIOVIG administered subcutaneously is indicated for:,1. Replacement therapy indications, Primary immunodeficiency disorders (PID).
KIOVIG administered intravenously is indicated for:,1. Replacement therapy indications, Primary immunodeficiency disorders (PID);, Symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.,2. Immunomodulation indications, Idiopathic thrombocytopenia purpura (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, Guillain Barré Syndrome;, Kawasaki Disease;, Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in adults., Multifocal Motor Neuropathy (MMN).,KIOVIG administered subcutaneously is indicated for:,1. Replacement therapy indications, Primary immunodeficiency disorders (PID).
KIOVIG administered intravenously is indicated for:,1. Replacement therapy indications, Primary immunodeficiency disorders (PID);, Symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.,2. Immunomodulation indications, Idiopathic thrombocytopenia purpura (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, Guillain Barré Syndrome;, Kawasaki Disease;, Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in adults., Multifocal Motor Neuropathy (MMN).,KIOVIG administered subcutaneously is indicated for:,1. Replacement therapy indications, Primary immunodeficiency disorders (PID).
KIOVIG administered intravenously is indicated for:,1. Replacement therapy indications, Primary immunodeficiency disorders (PID);, Symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.,2. Immunomodulation indications, Idiopathic thrombocytopenia purpura (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, Guillain Barré Syndrome;, Kawasaki Disease;, Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in adults., Multifocal Motor Neuropathy (MMN).,KIOVIG administered subcutaneously is indicated for:,1. Replacement therapy indications, Primary immunodeficiency disorders (PID).
KIOVIG administered intravenously is indicated for:,1. Replacement therapy indications, Primary immunodeficiency disorders (PID);, Symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.,2. Immunomodulation indications, Idiopathic thrombocytopenia purpura (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, Guillain Barré Syndrome;, Kawasaki Disease;, Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in adults., Multifocal Motor Neuropathy (MMN).,KIOVIG administered subcutaneously is indicated for:,1. Replacement therapy indications, Primary immunodeficiency disorders (PID).
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
